Neurotech International Limited (ASX:NTI)

Market Cap	17.84M
Revenue (ttm)	2.44M
Net Income (ttm)	-10.60M
Shares Out	1.05B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,855
Average Volume	883,998
Open	0.0170
Previous Close	0.0180
Day's Range	0.0170 - 0.0180
52-Week Range	0.0120 - 0.0740
Beta	0.42
RSI	48.46
Earnings Date	Oct 26, 2025

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.